The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

The aim of this study was to evaluate the effect of hGH administration on the growth pattern and FH in girls with TS.

Why It Was Studied

Shortness is the most frequent and quite disturbing characteristic of girls with Turner syndrome (TS).

Who Took Part

The abstract describes 123 girls taking part.

The age groups tagged for this paper are children, women only.

How the Study Was Run

The study group was comprised of 123 girls with TS who were cared for in their center.

The mean chronological age (CA) and bone age (BA) at hGH initiation were 11.5 +/- 2.5 years and 9.7 +/- 2.3 years, respectively.

The remaining 41 girls did not receive hGH and are designated as the untreated control group.

In both groups, gonadal steroids were given for pubertal initiation and maintenance.

What Was Measured

Topics PubMed links to this paper include Body Height, Growth, Human Growth Hormone and Turner Syndrome.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 123 girls.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.